Dare Bioscience, Inc. Cash Flow Statement
DARE|7 years of annual SEC 10-K data (FY2014-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 7 fiscal years. All figures from audited SEC 10-K filings.
Dare Bioscience, Inc. generated $5M in operating cash flow and $5M in free cash flow in FY2025. Free cash flow margin was 50087.0% of revenue.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.23 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|
| Net Income | -$4.1M | -$30.2M | -$30.9M | -$38.7M | -$23.3M | -$17.1M | -$22.1M |
| Depreciation & Amortization | $42.3K | $38.4K | $24.2K | $26.4K | $126.0K | $197.0K | $346.0K |
| Operating Cash Flow | $5.5M | -$38.9M | -$18.1M | -$28.8M | -$19.1M | -$16.6M | -$21.0M |
| Capital Expenditures | $573.0K | $629.4K | $63.1K | $14.5K | $225.0K | $7.0K | $180.0K |
| Free Cash Flow | $4.9M | -$39.5M | -$18.2M | -$28.8M | -$19.3M | -$16.6M | -$21.2M |
| FCF Margin | 50087.0% | -1406.3% | -181.5% | - | -24107.5% | -277016.7% | -3389.6% |